Murine immune responses to a Plasmodium vivax-derived chimeric recombinant protein expressed in Brassica napus by Choonghee Lee et al.
RESEARCH Open Access
Murine immune responses to a Plasmodium
vivax-derived chimeric recombinant protein
expressed in Brassica napus
Choonghee Lee1†, Hyung-Hwan Kim2,7†, Kyung Mi Choi1,3, Kyung Won Chung1, Yien Kyoung Choi1,3,
Mi Jung Jang1, Tong-Soo Kim4, Nam-Jun Chung5, Ho-Gun Rhie1, Ho-Sa Lee1, Youngjoo Sohn6, Hyuck Kim7,
Sung-Jae Lee1* and Hyeong-Woo Lee3,8*
Abstract
Background: To develop a plant-based vaccine against Plasmodium vivax, two P. vivax candidate proteins were
chosen. First, the merozoite surface protein-1 (MSP-1), a major asexual blood stage antigen that is currently
considered a strong vaccine candidate. Second, the circumsporozoite protein (CSP), a component of sporozoites
that contains a B-cell epitope.
Methods: A synthetic chimeric recombinant 516 bp gene encoding containing PvMSP-1, a Pro-Gly linker motif,
and PvCSP was synthesized; the gene, named MLC, encoded a total of 172 amino acids. The recombinant gene
was modified with regard to codon usage to optimize gene expression in Brassica napus. The Ti plasmid inducible
gene transfer system was used for MLC chimeric recombinant gene expression in B. napus. Gene expression was
confirmed by polymerase chain reaction (PCR), beta-glucuronidase reporter gene (GUS) assay, and Western blot.
Results: The MLC chimeric recombinant protein expressed in B. napus had a molecular weight of approximately
25 kDa. It exhibited a clinical sensitivity of 84.21% (n = 38) and a clinical specificity of 100% (n = 24) as assessed by
enzyme-linked immunosorbent assay (ELISA). Oral immunization of BALB/c mice with MLC chimeric recombinant
protein successfully induced antigen-specific IgG1 production. Additionally, the Th1-related cytokines IL-12 (p40),
TNF, and IFN-g were significantly increased in the spleens of the BALB/c mice.
Conclusions: The chimeric MLC recombinant protein produced in B. napus has potential as both as an antigen for
diagnosis and as a valuable vaccine candidate for oral immunization against vivax malaria.
Background
Plasmodium vivax, a causative agent of relapsing benign
tertian malaria, is the second most important malaria-
causing species; it afflicts several hundred million people
annually [1,2]. Malaria constitutes a major health pro-
blem and is closely associated with socioeconomic bur-
den in many temperate and most tropical countries. The
malaria situation of Korea peninsula is also not different
from other countries. It reemerged in the early 1990s
after two decade-long absence. Following government
intervention, reported cases of malaria decreased over
the course of several years. However, it is unlikely that
malaria has been completely eradicated from Korea; not
only is there a steady influx of travelers and workers
from countries where malaria is endemic, but the appear-
ance of failed treatment cases is also possible. Therefore,
vaccine development is needed for the eradication of
vivax malaria in Korea.
Compared to Plasmodium falciparum vaccine develop-
ment, less progress has been made on the development
of a vivax malarial vaccine due to the lower mortality
associated with vivax malaria and limitations in culturing
P. vivax in vitro. A vaccine to prevent vivax malaria is
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needed not only to prevent the morbidity associated with
the disease but also to prevent the potential spread of
malaria due to the reactivation of P. vivax hypnozoites in
non-endemic areas. It is associated with dormant liver
stage infections that can reactivate weeks to months after
primary infection and symptomatic disease [3-7].
In this study, a multistage plant-based vaccine con-
taining P. vivax merozoite surface protein-1 (PvMSP-1),
a Pro-Gly linker motif, and P. vivax circumsporozoite
protein (PvCSP). The MSP-1 gene encodes a 180 to 230
kDa glycoprotein that is a major merozoite surface pro-
tein in several Plasmodium species. PvMSP-1 has been
thoroughly investigated as a vaccine candidate against
the asexual blood stage of malaria [8-11]. PvCSP is a
sporozoite stage surface antigen. It consists of 18 to 20
short repeated sequences flanked by pre-repeat and
post-repeat areas. Across global isolates, the nine amino
acid tandem repeats were primarily GDRA(D/A)GQPA
for the VK210 subtype [12] and GNGA(A/G)GQAA for
the VK247 subtype [13]. CSPs from Korean P. vivax iso-
lates were also shown to contain the nine amino acid
tandem repeat sequences [14-16]. The region containing
the tandem repeats was cloned to make a recombinant
protein that has subsequently been used for malaria
diagnosis in patients, sero-epidemiological investigations,
and the production of monoclonal antibodies. Addition-
ally, this recombinant protein was reported to be a
viable vaccine candidate when assessed for immunogeni-
city [17-19].
Since the introduction of vaccine production using
transgenic plants by Mason et al. [20], oral immuno-
genicity has been demonstrated for several antigens
derived from human and animal pathogens expressed in
transgenic plants. For example, the hepatitis B surface
antigen was expressed in potatoes [21,22], a viral peptide
vaccine was expressed in Arabidopsis [23], and the MSP
antigens of P. falciparum and Plasmodium yoelii were
expressed in tobacco [24,25]. Additionally, oral immuni-
zation with edible vaccines that have been produced in
transgenic plants may stimulate immune responses
against their target pathogens [26,27]. However, com-
mercially available vaccines based on transgenic plants
have not yet to be produced.
In this study, the antigenicity of a chimeric recombi-
nant protein expressed in transgenic Brassica napus was
investigated and evaluated as an edible vaccine candi-
date against vivax malaria.
Methods
Blood sample collection
Patients exhibiting clinical signs of malaria infection at
the Public Health Centers in Gimpo-si and Paju-si of
Gyeonggi-do, South Korea, were examined for malaria
parasites. Approximately 3 ml of blood was collected
from each symptomatic patient. Thin and thick blood
smears were prepared for microscopic examination
(magnification × 1,000). Blood samples were transported
to the Korean National Institute of Health (KNIH),
where the sera were separated and stored at -20°C for
future examination. Informed consent was obtained
from all patients. All samples were collected under
human use protocols that were reviewed and approved
by the Human Ethics Committee of the Korean National
Institute of Health (Cheongwon, Korea).
Gene construction strategy for the chimeric recombinant
protein
The chimeric recombinant protein was designed as a
biphasic antigen to target both the blood and the early
liver cell stages of P. vivax infection. One of the epitopes
used in the current study was derived from the PvMSP-1
gene of the P. vivax Belem isolate; it encompasses
nucleotides 4,925 to 5,239 (315 bp), which correspond to
the interspecies conserved block 10 (ICB10) (GenBank
Access No. AF435594) [28]. The nucleotide sequence of
PvMSP-1 gene was modified for optimal expression in
plants, as shown in Figure 1. The other epitope was
synthesized four repeats of GDRAAGQ(P/A)A for the
Figure 1 Nucleotide differences between the original (ICB10ori, GenBank access no. AF435594) and the modified (MLCICB10)
nucleotide sequences of P. vivax MSP-1.
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expression of PvCSP VK210 subtype (AF316582)
[14-16,28]. The ICB10 of PvMSP-1 and PvCSP VK210
subtype were linked via Pro-Gly repeat motifs. The linker
region contained five or six Pro-Gly repeats surrounding
an internal sequence of 10 amino acids, TLQTRIDEFG
(Figure 2A) [29,30].
Construction of plasmids for transgenic plants
To construct the codon-optimized chimeric gene, com-
plementary strands of the oligonucleotides for PvMSP-1,
the linker, and PvCSP were synthesized with XbaI sites
at the 5’ end of PvMSP-1 and BamHI sites at the 3’ end
of PvCSP. These synthesized oligonucleotides were
linked by T4 ligase in the order of 5’-PvMSP-1-linker-
PvCSP-3’ (MLC). This gene was then cloned into the
pCR2.1 cloning vector (Invitrogen Co., Carlsbad, CA,
USA) subsequently transformed into Escherichia coli
INVaF’ according to the manufacturer’s instructions.
Resulting transformants were confirmed by digestion
with EcoRI. Plasmids were then purified and digested
with XbaI and BamHI restriction enzymes. This gene
fragment was then inserted into the protein expression
vector pHSS2 vector (Nexgen Co., Seoul, Korea) under
the strong constitutive cauliflower mosaic virus 35S
(CaMV35S) promoter with a beta-glucuronidase (GUS)
reporter gene and a neomycin resistance gene (Figure
2B). The resulting plasmid was amplified in E. coli
DH5a.
Transformation, selection, and regeneration of
transgenic plants
Brassica napus was used as the host plant for transforma-
tion. Plant cultivation was performed under greenhouse
conditions. Transgenic plants were obtained using the
cotyledon agrobacterial transformation technique [31].
To acquire cotyledon explants, seeds were germinated in
a culture room at 25°C in a photoperiod of 16 h light/8 h
dark for 4 days with the light supplied by cool-white day-
light fluorescent lights. The seeding medium contained
0.2% Murashige and Skoog medium with Gamborg
vitamin B5 (MSB5) salts, 1% w/v sucrose, 0.05% 2-(N-
morpholino) ethanesulfonic acid (MES), and 0.6% plant
Figure 2 (A) Gene construction scheme for the expression of the MLC chimeric recombinant protein. LB and RB indicate the left and
right borders of the T-DNA region, which is stably integrated into nuclear chromosomal DNA during Agrobacterium-mediated DNA delivery. TSS
represents the translation start site, and SEKDEV (Serine-Glutamate-Lysine-Aspartate-Glutamate-Valine) stands for secretion signal. Additionally, this
signal promotes exact oligomerization. The selectable marker used for plant transformation is the nptII gene, which confers kanamycin resistance.
The GUS reporter protein was used as a marker to enable rapid screening in selective steps of plant regeneration. (B) Nucleotide and deduced
amino acid sequence of the MLC chimeric recombinant gene. It is comprised of a modified PvMSP-1 (PvMSP1ICB10, AF435594), a linker (Pro-Gly
repeat, underlined), and PvCSP (PvCSPTR, AF316582).
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agar. Cotyledon explants excised from in vitro grown
seedlings were cut into 0.5 to1 cm pieces, and the apical
shoot tip was removed. Agrobacterium tumefaciens used
for infection and co-cultivation; it was grown in Yeast
Extract Peptone (YEP) media (0.5% yeast extract, 0.5%
peptone, and 0.5% sucrose, pH 7.2) with kanamycin over-
night to an optical density of 1.0 at 600 nm. Cotyledons
were immersed in the infection media (37 ml liquid
infection medium consisting of 0.4% MSB5 salts, 2%
sucrose, 1 μg/ml of 2,4-D, 2 ml dimethyl sulfoxide
(DMSO) and a 10 ml pellet of Agrobacterium culture)
and incubated for 20 min [32]. Excess bacterial culture
was removed by blotting with filter paper and the cotyle-
dons were co-cultivated on filter paper-covered co-
culture medium (0.05% MES and 0.6% plant agar in
infection medium) for two days. Plates were then trans-
ferred to dark conditions at 4°C for 2 days. The cotyle-
dons were placed on a selection medium consisting of
0.4% MSB5 salts, 3% w/v sucrose, 0.05% MES, 2 μg/ml
6-benzylaminopurine (BA), 0.01 μg/ml a-naphthalene
acetic acid (NAA), and 0.6% plant agar supplemented
with 15 μg/ml kanamycin for selective pressure, 500 μg/ml
carbenicillin to eliminate the Agrobacterium and 2 μg/ml
silver nitrate to prevent cell necrosis. The calluses in the
selection medium were incubated at 25°C and then trans-
ferred to fresh medium every two weeks. The same selec-
tion medium was used for shoot regeneration medium.
From GUS-positive explants, regenerated shoots that had
elongated to 2 to 3 cm in length were transferred to root-
ing medium. Approximately 6 weeks later, green shoots of
approximately 5 to 6 cm in length were isolated and
placed in Magenta boxes (Sigma, St. Louis, MO, USA)
containing rooting medium and carbenicillin and kanamy-
cin at the same concentrations as shoot regeneration med-
ium. Root initiation was observed within two to three
weeks, and roots developed into mature plants within one
month.
GUS (beta-glucuronidase) reporter gene assay
Regenerated shoots were subjected to histochemical
analysis for GUS expression. Identification of GUS activ-
ity was performed using 5-bromo-4 chloro-3-indolyl
b-D-glucuronide (X-Gluc) as a histochemical substrate.
For each shoot, 0.1 g was incubated in X-Gluc solution
(0.5 mM each of potassium ferro- and ferri-cyanide,
0.3% Triton X-100 and 1.9 mM X-Gluc dissolved in
dimethylformamide) at 37°C for 1 h. A GUS-positive
response was revealed by a green-blue-colored solution,
whereas a negative signal was indicated by a yellow-
coloured solution. GUS activity was measured by com-
paring the optical densities of wild type plants (used as
a negative control), transgenic plants with empty vector
pHSS2 (used as a positive control) and transgenic plants
with pHSS2-MLC as the target product.
DNA extraction from transgenic plants
For DNA extraction, 200 mg of leaves were homoge-
nized in 400 μl of extraction buffer containing 0.2 mM
Tris-HCl (pH 7.5), 250 mM NaCl, 25 mM ethylenedia-
minetetraacetic acid (EDTA), and 0.5% sodium dodecyl
sulfate (SDS). Mixtures were transferred to 1.5 ml tubes
that were then agitated and centrifuged. Supernatants
were collected and combined with 600 μl chloroform:
isoamyl alcohol (24:1, v/v) and vortexed. After centrifu-
gation, supernatants were precipitated with an equal
volume of isopropanol; pellets were washed twice with
70% ethanol. The washed pellets were then dissolved in
20 μl TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH
8.0). DNA samples were verified by electrophoresis on a
1% agarose gel. The extracted plant genomic DNA was
used as a template for polymerase chain reaction (PCR).
PCR analysis and sequencing of MLC and nptII genes
Regenerated plants transformed with A. tumefaciens
GV3101 harbouring the pHSS2 plasmid containing the
nptII and MLC genes were identified by PCR analysis.
PCR analysis was performed in reaction mixtures contain-
ing approximately 0.5 to 1 μg genomic plant DNA under
the following conditions: 94°C for 1 min, 30 cycles of 94°C
for 1 min, 62°C for 1 min and 72°C for 1 min, and a final
extension of 72°C for 10 min in a TECHNE PCR thermo-
cycler (Burlington, NJ, USA). The 516-bp and 800-bp PCR
products were obtained using primer sets specific for the
MLC gene (MLC-F, 5’-TTCTAGAGTGCATTGATAC-
CAACGTTCC-3’ and MLC-R, 5’-TAGGATCCCCAGCT
GGTTGACC-3’) and nptII gene (NPTII-F, 5’-GAACAA-
GATGGATTGCACGC-3’ and NPTII-R, 5’-GAAGAA
CTCGTCAAGAAGGC-3’), respectively. To confirm
nucleotide sequences, plasmid DNA of A. tumefaciens
GV3101 (pHSS2-MLC) and the PCR products of the
transgenic plant genomic DNA samples were analyzed by
Bionics Inc. (Seoul, Korea).
Preparation of plant protein extracts for immunoblot
analysis
To prepare plant protein extracts for enzyme-linked
immnunosorbent assay and western blot analysis, plant
tissue samples were frozen in liquid nitrogen, ground,
and homogenized in extraction buffer [10% trichloroace-
tic acid (TCA) in acetone with 2% b-mercaptoethanol]
[33]. For 1 g of fresh plant tissue, 3 ml buffer was used.
Extracts were placed at -20°C for 30 min and then centri-
fuged at 7,000 × g for 30 min at 4°C. Supernatants were
discarded, and the remaining white pellet was washed
twice with 10 ml acetone. Plant protein extracts were
separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), and proteins were trans-
ferred onto polyvinylidene fluoride (PVDF) membranes
using a semi-dry transfer method (Bio-RAD, Hercules,
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CA, USA). For western blot analysis, membranes were
probed with antibodies directed against PvMSP-1 (Joong-
kyem Antibody therapeutics, Shiheung, Korea), or PvCSP
(supported by Wirtz RA, CDC, USA). Wild type and
pHSS2 empty vector-inserted transgenic plants were
used as negative controls.
Immunization of mice with MLC chimeric recombinant
protein
Fifteen male BALB/c mice, aged six weeks (Orient Bio
Inc, Seongnam, Korea), were divided into three groups.
Group A mice were fed 1 g of ground leaves from non-
transgenic B. napus dissolved in 1.5 ml PBS. Group B
mice were fed 200 μg of ground leaves from MLC-trans-
genic B. napus. Group C mice were fed 1 g of ground
leaves from MLC-transgenic B. napus. All mice were
provided food and water ad libitum. However, mice
were fasted overnight before oral administration of the
recombinant protein. Oral administration was performed
twice at four-week intervals. Three weeks after the last
oral feeding, mice were sacrificed and spleen and blood
samples were taken. Sera were analyzed by ELISA and
by cytokine and immunoglobulin sub-typing assays. All
mouse experiments were performed following protocols
approved by the Kyung Hee University Institutional Ani-
mal Care and Use Committee.
Enzyme-linked immunosorbent assays
Sera from patients infected with P. vivax were analyzed
for the presence of antigen-specific antibodies using 96-
well plates coated overnight at 4°C with 0.5 μg/ml per
well purified MLC chimeric recombinant protein dis-
solved in phosphate buffer saline (PBS), pH 7.4. Patient
serum samples were diluted 1:100 (v/v) in blocking buffer
(0.25% PBS-Tween 20 with 1% bovine serum albumin,
pH 7.4) added to the plates and incubated for 1 h. After
washing the wells with a 0.05% PBS-Tween 20 solution
three times, plates were incubated with peroxidase-
conjugated goat anti-human IgG secondary antibody
diluted 1:1,000 (v/v, Sigma). For color development,
100 μL of 2.2’-azino-di-(3-ethyl-benzthiozoline-6-sulfonic
acid) (ABTS) peroxidase substrate (Kirkegaard & Perry
Laboratories, Gaithersburg, MD, USA) was added to each
well and incubated at room temperature for 30 min. The
absorbance of the mixture was measured at 405 nm
(Molecular Devices, Sunnyvale, CA, USA). The cut-off
value was taken as the mean ± 2 standard deviations of
the negative samples.
Cytokine and immunoglobulin assays
Spleens from orally immunized mice were minced with
a razor and added to 1 ml ice cold endotoxin-free PBS
containing a protease inhibitor cocktail (Roche) and
0.1% Igepal CA-630 nonionic detergent (Sigma) [34].
Spleen lysates were then centrifuged at 20,000 × g for
10 min. Supernatants were collected and stored at -20°C
for cytokine analysis. The presence of IL-2, IL-12(p40),
IFN-g, and TNF in spleen lysates was determined using
Bio-Plex Kits (Bio-Rad) according to the manufacturer’s
protocols. The results were analyzed using Bio-Plex
Manager 5.0 software (Bio-Rad). To analyze the isotype
of the antibodies produced by oral immunization, the
mouse immunoglobulin isotyping kit (Millipore, Biller-
ica, MA, USA) was used. Briefly, all sera collected 3
weeks after the final immunization were diluted with
the MILLIPLEX MAP Assay Buffer at 1:25,000 (v/v).
The serum concentrations of each antibody isotype
(IgG1, IgG2a, IgG2b, IgG3, IgA, and IgM) were mea-
sured by Luminex 100™ IS (Luminex, Austin, TX,
USA).
Statistical analysis
All data are presented as the means ± standard deviation;
results were statistically analyzed. IL-2, IL-12 (p40), IFN-
g, and TNF levels among the three groups were com-
pared using one-way ANOVA followed by Bonferroni’s
multiple comparison tests. A P-value of < 0.05 was con-
sidered to be statistically significant.
Results
Construction of an MLC chimeric recombinant protein
The MLC chimeric recombinant gene was synthesized
using the ICB10 of the P. vivax MSP-1 gene and nine tan-
dem repeats from the P. vivax VK210 subtype CSP gene.
The PvMSP-1 gene was modified to optimize gene expres-
sion in plants without changing amino acid codon usages
as shown in Figure 1. Following optimization, the synthetic
PvMSP-1 gene sequence was revealed to have 75.6% iden-
tity with the Belem isolate of P. vivax (Figure 1). The lin-
ker region contained six Pro-Gly repeats before and five
after an internal sequence of 10 amino acids, ‘TLQTRI-
DEFG’ (Figure 2A). The last G of the Pro-Gly repeat over-
lapped with the start of the CSP repeats. The repeat
sequence of PvCSP was added after the linker region with
two ‘GDGAAGQAA’ and two ‘GDRAAGQPA’ sequences.
The resulting synthetic MLC chimeric recombinant gene,
named the MLC gene, was composed of 105 amino acids
from PvMSP-1, a 31-amino-acid linker, and 36 amino
acids from tandem repeats of PvCSP VK210 subtype
(Figure 2A).
Transformation of the MLC chimeric recombinant gene
into B. napus
The MLC chimeric recombinant gene was inserted into
the pHSS2 vector at XbaI and BamHI sites for expres-
sion in B. napus. The resulting expression vector was
referred to as pHSS2-MLC. It was transformed into
B. napus using an Agrobacterium-mediated DNA
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delivery system (Figure 2B). Three transgenic plant
groups were constructed: Group I, non-transgenic plants
(wild type); Group II, plants transformed with A. tumefa-
ciens GV3101/pHSS2 empty plasmid (negative control),
and Group III, plants transformed with A. tumefaciens
GV3101/pHSS2-MLC. Non-transgenic plants showed a
yellow color in the GUS assay (Figure 3A), with an optical
density of 0.23 ± 0.02 (n = 4, Figure 3B). B. napus plants
transformed with the A. tumefaciens GV3101/pHSS2 plas-
mid produced 85 calluses, 62 of which exhibited a green
spot in the GUS reporter gene assay (Figure 3A), with an
optical density of 2.66 ± 0.05 (n = 4, Figure 3B). These
results indicated the presence of the target plasmid in
plants. Of the 32 calluses obtained from the transgenic
B. napus plants with A. tumefaciens GV3101/pHSS2-
MLC, 23 showed a positive response in the GUS reporter
gene assay (Figure 3A), with an optical density of 2.59 ±
0.16 (n = 4, Figure 3B). Up to 90% of the GUS reporter
gene-expressing plants were positive when screened for
the presence of the recombinant gene by PCR analysis.
The PCR products amplified with MLC specific primer
consistently included the expected 550-bp band in MLC
transformed plants, while PCR on the non-transformed
plants failed to amplify the target MLC gene. PCR analysis
using an nptII-specific primer set showed products of
approximately 800 bp (Figure 4A). Further, DNA sequen-
cing analysis of genomic DNA from transgenic B. napus
plants demonstrated identical sequences to the MLC chi-
meric recombinant gene.
Immune response to MLC chimeric recombinant protein
in BALB/c mice
To investigate the antigenicity of the MLC chimeric
recombinant protein expressed in B. napus, the protein
was purified using the TCA-acetone-based protein pre-
cipitation method. SDS-PAGE analysis determined the
molecular mass of the protein to be approximately
25 kDa (Figure 4B. lane 2). As shown in Figure 4B, the
recombinant protein reacted with anti-PvMSP-1 (lane 3)
and anti-PvCSP antibodies (lane 4). The protein exhib-
ited a clinical sensitivity of 84.21% (n = 38) and 100%
specificity (n = 24) in ELISA (Figure 5). Therefore, the
MLC chimeric recombinant protein displayed antigenic
properties in vitro.
Serum samples were collected from each group of mice
three weeks after the final immunization and tested for
MLC chimeric recombinant protein-specific antibodies
using Western blot analysis. Antigen-specific antibodies
were not detected in PBS fed mice (Figure 6A) or in mice
Figure 3 Detection of GUS activity in explants of regenerated
B. napus plants. (A) GUS reporter activity as measured by color
change. (B) GUS reporter activity was quantified by measuring
sample optical densities at 595 nm.
Figure 4 (A) Confirmation of transformed B. napus by PCR
amplification of the MLC gene (I) and the nptII gene (II). Lanes
1, 3-6, transformed explants; Lane 2, non-transformed explant. (B)
Expression and confirmation of the MLC chimeric recombinant
protein in B. napus. Lane 1, wild type plant; Lane 2, pHSS2-MLC
transgenic plant; Lane 3, reacted with anti-PvMSP antibodies; Lane
4, reacted with anti-PvCSP antibodies.
Figure 5 Scattergram of absorbances measured by ELISA using
MLC chimeric recombinant protein expressed in B. napus. Sera
from healthy individuals and malaria patients infected with P. vivax
were used.
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fed 200 μg of chimeric recombinant protein (Figure 6B).
However, two of the five mice fed 1 μg of MLC chimeric
recombinant protein showed a positive reaction by Wes-
tern blot (Figure 6C). In an isotype analysis, IgG1 levels
increased in the sera of BALB/c mice fed with extract of
pHSS2-MLC transformed B. napus. The mean amount of
IL-2 expression in spleen was 11.28 ± 1.66 pg/ml in Group
1 mice, which were fed only PBS, 12.44 ± 0.89 pg/ml in
Group 2 mice, fed B. napus transformed with empty
expression vector only (pHSS2), and 13.68 ± 1.38 pg/ml in
Group 3 mice, which were fed B. napus that expressed the
MLC chimeric recombinant protein. There were no signifi-
cant differences between groups (Figure 7A). The mean
amount of IL-12(p40) expression was 283.97 ± 19.75 pg/ml
in Group 1, 270.54 ± 14.65 pg/ml in Group 2, and 410.77 ±
54.58 pg/ml in Group 3. There was a significant difference
between Groups 1 and 3, and between Groups 2 and 3, but
there was no statistically significant difference between
Groups 1 and 2 (P < 0.05) (Figure 7B). The mean amount
of IFN-g expression was 18.50 ± 5.53 pg/ml in Group 1,
16.61 ± 0.98 pg/ml in Group 2, 41.80 ± 10.88 pg/ml in
Group 3. There was a significant difference between
Groups 1 and 3, and between Groups 2 and 3, but there
was no statistically significant difference between Groups 1
and 2 (P < 0.05) (Figure 7C). The mean amount of TNF-a
expression was 35.56 ± 11.94 pg/ml in Group 1, 85.98 ±
7.90 pg/ml in Group 2, and 188.90 ± 22.74 pg/ml in Group
3. There was a significant difference between Groups 1 and
3, between Groups 2 and 3, and between Groups 1 and 2
(P < 0.05) (Figure 7D). Therefore, the Th1-related cyto-
kines, IL-12(p40), IFN-g, and TNF were expressed in the
spleens of BALB/c mice orally immunized with ground
leaves from transgenic plants that expressed the MLC chi-
meric recombinant protein.
Discussion
A number of malarial proteins that have been demon-
strated to be potential vaccine candidates are currently
in various stages of pre-clinical and clinical trials
[35-37]. Many of these trials are based on MSP, CSP,
and apical membrane antigen-1 (AMA-1) proteins
[38-41]. A vast majority of the vaccine candidates target
P. falciparum, with fewer P. vivax candidates in vaccine
development [42]. Presently, there are only two P. vivax
subunit vaccine candidates undergoing clinical develop-
ment and only a modest number of other candidates in
pre-clinical trials [5]. Additionally, there are several trials
of chimeric malaria vaccines constructed using MSP-8/
MSP-1 and AMA-1/MSP-1. However, although these
chimeric vaccines successfully induced high antibody
responses, they failed to protect against infectious chal-
lenge with parasites [29,37,43].
In the present study, an MLC chimeric recombinant
protein was developed which containing the ICB10
region of MSP-1 and four tandemly repeated sequences
of nine amino acids from CSP VK210 subtype. The strat-
egy of gene construction was the first challenge in mak-
ing an MLC chimeric recombinant protein for a
multistage combination vaccine directed against both
merozoite and sporozoite forms. B. napus was selected
for the expression of an MLC chimeric recombinant
gene. The expression and purification of recombinant
proteins in plants has several advantages compared to
other commercial expression systems. First, plant-based
vaccines do not contain endotoxin, which is produced
during bacterial culture and purification steps. Addition-
ally, the biomass produced in plants is greater than other
systems, thereby reducing the cost and allowing rapid
industrialization and manufacturing [22,23]. Also, if
edible plants are utilized, plant-based vaccines can be
eaten raw without modification in factories. Finally,
expression of candidate vaccine proteins in plants allows
for the complete synthesis of target antigens that are able
to induce an active immune response in animals. In light
of these advantages, transgenic plants are now being gen-
erated and investigated for use in the production of vac-
cines against various human pathogens [20,21,24,26].
This study employed classical techniques for the gen-
eration of transgenic B. napus to produce a transgenic
plant containing the MLC chimeric recombinant protein
gene under the control of the constitutive CaMV35S pro-
moter [21]. Additionally, the nucleotide sequence of
ICB10 region of MSP-1 was modified to optimize its
expression in plants (Figure 1). The modified sequence
has 75.6% nucleotide sequence homology and 100%
amino acid sequence homology compared to the original
ICB10 sequence from the P. vivax Belem isolate; further,
it was successfully expressed in B. napus (Figure 4B, lane
2). Purified MLC chimeric recombinant protein reacted
well with the sera of vivax malaria patients (Figure 5).
Therefore, this reagent could be used to sero-diagnose
patient with vivax malaria. Although not all of the mice
orally immunized with 1 g MLC chimeric recombinant
Figure 6 Antibody induction in BALB/c mice orally immunized
with transgenic B. napus that expresses the MLC chimeric
recombinant protein. (A) BALB/c mice fed PBS only; (B), BALB/c
mice fed 200 μg of chimeric recombinant protein; (C), BALB/c mice
fed 1 g of chimeric recombinant protein; (D), positive control-
reacted with anti-his antibody.
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protein produced antigen-specific antibodies, MLC chi-
meric recombinant protein-specific IgG1 antibodies were
detected in two (40%) of the five mice (Figure 6). These
observations indicate that the MLC chimeric recombi-
nant protein has the possibility to trigger Th-2 immune
responses. Il-12(p40), TNF, and IFN-g were detected in
the spleens of BALB/c mice orally immunized with the
MLC chimeric recombinant protein (Figure 7). However,
IL-2 was not produced in significant amounts. Together
with these results, MLC chimeric recombinant protein
induced both Th-1 and Th-2 immune responses in
BALB/c mice effectively.
Conclusions
Based on this work, the MLC chimeric recombinant
protein produced in transgenic B. napus plants has
potential as a P. vivax vaccine candidate. There are sev-
eral merits unique to B. napus for the production of
anti-malarial vaccines, including the ease of cultivation
of B. napus even in the absence of certain nutrients;
Figure 7 Cytokine expression in the spleens of BALB/c mice orally immunized with transgenic B. napus that expresses the MLC
chimeric recombinant protein. Concentrations of IL-2, IL-12(p40), IFN-g, and TNF-a were measured. Group 1, BALB/c mice fed PBS only; Group
2, BALB/c mice fed non-transformed plant; Group 3, BALB/c mice fed MLC chimeric recombinant protein. Values represent the mean ± SD (n =
3). * Significant difference between Groups 1 and 3 (P < 0.05). †Significant difference between Groups 2 and 3 (P < 0.05).
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together, these advantages allow for rapid industrializa-
tion and manufacturing. Additionally, because of the
convenience of ingesting this plant, populations can be
given the vaccine as part of a routine diet. This strategy
will decrease the cost of vaccination against malaria in
developing countries. Additionally, trials for developing
edible plant vaccines will contribute to a basic under-
standing of the development of vivax malaria vaccines.
In conclusion, the MLC chimeric recombinant protein
might be helpful in the serodiagnosis and vaccine devel-
opment against P. vivax.
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